Kenvue Inc. (NYSE:KVUE - Get Free Report) announced a quarterly dividend on Wednesday, April 16th, RTT News reports. Investors of record on Wednesday, May 14th will be given a dividend of 0.205 per share on Wednesday, May 28th. This represents a $0.82 dividend on an annualized basis and a yield of 3.50%. The ex-dividend date is Wednesday, May 14th.
Kenvue has a dividend payout ratio of 66.7% indicating that its dividend is sufficiently covered by earnings. Analysts expect Kenvue to earn $1.24 per share next year, which means the company should continue to be able to cover its $0.82 annual dividend with an expected future payout ratio of 66.1%.
Kenvue Stock Up 3.0 %
Shares of NYSE KVUE traded up $0.69 during midday trading on Friday, reaching $23.42. 22,595,142 shares of the company's stock were exchanged, compared to its average volume of 17,088,173. The stock has a market capitalization of $44.93 billion, a PE ratio of 44.19, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02. Kenvue has a 52-week low of $17.67 and a 52-week high of $24.46. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The business's fifty day moving average price is $22.91 and its two-hundred day moving average price is $22.41.
Kenvue (NYSE:KVUE - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Analysts forecast that Kenvue will post 1.14 EPS for the current year.
Analyst Upgrades and Downgrades
A number of equities analysts recently commented on the company. Royal Bank of Canada reiterated a "sector perform" rating and issued a $24.00 price target on shares of Kenvue in a research note on Monday, February 3rd. Redburn Atlantic began coverage on shares of Kenvue in a report on Thursday, April 10th. They issued a "neutral" rating and a $23.50 price objective for the company. UBS Group dropped their target price on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a report on Friday, February 7th. Barclays lowered their price objective on shares of Kenvue from $23.00 to $22.00 and set an "equal weight" rating for the company in a research report on Monday, April 14th. Finally, Evercore ISI began coverage on Kenvue in a report on Monday, March 24th. They set an "in-line" rating and a $25.00 target price for the company. Eight investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $24.42.
Read Our Latest Stock Report on KVUE
About Kenvue
(
Get Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
See Also
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
